AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors
In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned the abstracts and companies he would be tracking during the upcoming AAIC.
This could include aducanumab by Biogen Inc (NASDAQ: BIIB) and solanezumab by Eli Lilly and Co (NYSE: LLY).
AAIC is scheduled between July 18 and 22. Analyst Mark Schoenebaum noted the planner for abstracts that they would be will be tracking:
Saturday - July 18
POSTER
Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Exhibit Hall E
IC-P-030
12:15pm - 2:15pm
Tuesday - July 21
POSTER
Safety of Solanezumab in the Expedition-EXT Study up to 2 Years in a Mild to Moderate Alzheimer's Disease Population
Exhibit Hall D
P3-285
9:30am - 4:15pm
ORAL
Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Hall E
03-01-04
2:00pm - 3:30pm
Wednesday – July 22
ORAL
Delayed-Start Analyses of up to 3.5 Years in the Phase 3 Solanezumab Expedition Program in Mild Alzheimer's Disease
Ballroom A
04-03-02
8:00am - 9:30am
POSTER
Rvt-101, a 5-HT6 Receptor Antagonist, As Adjunctive Therapy with Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Responder Analysis
Exhibit Hall E
P4-302
9:30am - 4:15pm
ORAL
Aducanumab (BIIB037), an Anti-Amyloid Beta Monoclonal Antibody, in Patients with Prodromal or Mild Alzheimer's Disease: Interim Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1B Study
146
04-04-05
2:00pm - 3:30pm
ORAL
The Efficacy of Rvt-101, a 5-HT6 Receptor Antagonist, As an Adjunct to Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Completer Analysis of a Phase 2b Study
Hall E
DT-01-04
2:00pm - 3:30pm
Axovant Investor Briefing
Doors open at 5:15pm
Presentation begins 5:45pm
Marriott Marquis, Georgetown Room, 900 Massachusetts Ave. Northwest, Washington, DC 20001
Latest Ratings for BIIB
Jun 2015 | Leerink Swann | Maintains | Outperform | |
Jun 2015 | Leerink Swann | Reiterates | Outperform | |
Apr 2015 | Citigroup | Maintains | Buy |
View More Analyst Ratings for BIIB
View the Latest Analyst Ratings
See more from Benzinga
Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year
Chinese Internet Pair Trade? Mizuho Upgrades Sohu, Downgrades Youku
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.